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1. Introduction  
Alzheimer’s disease (AD) is the most common form of dementia in the aging population. It 
is a complex disease that affects many brain functions and is characterized by a progressive 
impairment of cognitive abilities, such as memory, learning and social skills. AD was first 
described over hundred years ago by the German psychiatrist Dr. Alois Alzheimer, 
reporting of the in due course characteristic pathological changes postmortem discovered in 
his 56 years old patient Auguste D (Alzheimer, 1907). The disease is obviously devastating 
for the patients and affects everyday life for both patients and their families, but it also 
generates economical challenges for the heath-care system and the society as the elderly 
population is growing (Wimo & Winblad, 2008). Although research regarding AD is 
intensive worldwide and new results do get a greater understanding of the causes of the 
disease, the exact mechanisms and underlying cause behind AD are still unsolved. The 
disease progresses over decades leading to premature death. There are no disease-
modifying therapies for AD available, and the current treatment might provide 
symptomatic relief and slower disease progression.  
The new imaging technologies based on structural and functional processes in the brain 
enable early diagnosis and may also differentiate between types and severity of 
neurodegeneration. Mild cognitive impairment (MCI) is closely related to AD and can be 
considered as a transitional stage between normal cognition and dementia. MCI is 
characterized by either isolated memory impairment or impairment in several cognitive 
domains, but not of sufficient severity to meet diagnostic criteria for AD (Petersen et al., 
2001). Although MCI is associated with an increased risk of developing AD, about half of 
MCI patients progress to AD at a rate of approximately 10%–15% per year, but 
approximately half do not develop AD even after follow-up periods as long as 10 years 
(Ewers et al., 2010; Ganguli & Petersen, 2008; Ganguli et al., 2011). 
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A clinical diagnosis of AD is assessed by several investigations including medical history 
and neuropsychological criteria such as the NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and 
Related Disorders Association) (McKhann et al., 1984), but a definite diagnosis of AD can 
only be done postmortem. Therefore, development of efficient prevention therapies for AD 
would greatly benefit from a diagnosis at a prodromal stage of the disease. Positron 
emission tomography (PET) is considered a unique diagnostic tool that enables early 
detection of pathology that facilitates prediction of AD and following the progression in vivo 
(Långström et al., 2007). Highly specific and sensitive biomarkers are of great value to assess 
therapeutic efficacy clinically and in terms of clearance of histopathological lesions and 
decelerated neurodegeneration. 
 
 
Fig. 1. Model of the temporal pattern of neuropathologic changes in AD neocortex. The 
figure shows that there is increase in amyloid plaques (Aβ) in the prodromal phase, 
followed by a progressive loss of neurons and a formation of neurofibrillary tangles in 
parallel with deteriorating cognitive capacities in the intermediate cognition state, MCI and 
later in AD. Figure adapted from Långström et al. (2007). 
2. Pathology 
AD is characterized neuropathologically by cerebral neuronal loss and the main 
histopathological hallmarks are intracellular neurofibrillary tangles consisting of 
hyperphosphorylated tau and extracellular β-amyloid (Aβ) deposits found as senile plaques 
in the brain parenchyma. These plaques are formed from insoluble A peptides, fibrils and 
oligomers, that originate through processing of the larger Amyloid Precursor Protein (APP) 
(Selkoe & Schenk, 2003).  
2.1 Pathological protein, Aβ 
The A containing plaques induce cell death and are formed during early disease 
progression long before the patient feels any symptoms in the prodromal phase of the 
disease (Braak et al., 1998; Ingelsson et al., 2004) (figure 1). Whether the formation of plaques 
is the major underlying event of the neurogenerative process in AD is a matter of debate. 
The amyloid cascade hypothesis is today one of the leading theories and suggests that Aβ 
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depositions in the brain are the central lesion in the pathogenesis of AD (Korczyn, 2008). 
However, although the A plaques appear in the brain prior to the neurofibrillary tangles, it 
has been demonstrated that the neurofibrillary tangles are better correlated with neuronal 
loss and cognitive decline than to A plaques (Schönheit et al., 2004). Furthermore, plaques 
are present in cognitively normal elderly subjects without any signs of neurodegeneration 
(Hellström-Lindahl et al., 2004; Villemagne et al., 2008). Nonetheless, there is evidence that 
amyloid are associated with severity of dementia (Näslund et al., 2000).  
Since it became possible to measure A in vivo in the brain by PET (Klunk et al., 2004), Aβ 
plaques has became a disease-defining pathologic marker of AD. However, the plaques 
might play an important role in the pathophysiological mechanisms of the disease. Various 
strategies to prevent aggregation, increase Aβ clearance or alter APP metabolism sought for 
the development of new treatment strategies of AD 
2.1.1 Amyloid imaging 
Amyloid imaging using PET has developed rapidly in recent years. With the development 
of the amyloid-imaging PET tracer [11C]PIB (N-methyl-[11C]-2-(4-methylaminophenyl)-6-
hydroxy-benzothiazole), a derivate of the widely used dye for plaques thioflavin-T, the 
possibility to study the presence of amyloid in the brains of AD patients in early stages of 
the disease with PET became an important tool (Archer et al., 2006; Klunk et al., 2004; 
Mintun et al., 2006; Nordberg, 2004). [11C]PIB has a high affinity for aggregated Aβ, crosses 
the blood brain barrier (BBB) easily, has low toxicity and makes it possible to visualize 
plaque and vascular amyloid deposits in the brain. [11C]PIB is today the most commonly 
used radioligand in the assessment of amyloid plaques in the living human brain using PET, 
although several new compounds are under development (see table 1) (Henriksen et al., 
2008; Ono, 2009). However, the exact nature of the mechanism for the binding of [11C]PIB 
and other amyloid ligands to Aβ in the form of β-pleated sheets is still unknown.  
One of the central issues regarding the PIB-amyloid binding in the AD brain is thus to 
understand the mechanisms and binding properties of the ligand. It has been demonstrated 
that [11C]PIB has high affinity for fibrillar Aβ and binds to the β-sheet structure of the Aβ 
fibrils (Klunk et al., 2003). It has also been shown that [11C]PIB in nanomolar concentrations 
does not bind to neurofibrillary tangles (Bacskai et al., 2007; Ikonomovic et al., 2008; Kadir et 
al., 2011; Rosen et al., 2011). 
2.1.2 Neuroinflammation (gliosis) 
The widespread cellular degeneration and neuronal loss in AD is accompanied by reactive 
gliosis (Kadir et al., 2011). Close to the amyloid plaques both astrocytes and microglia are 
clustered, probably as a result of a starting neuroinflammatory process (Akiyama et al., 
2000). Activated microglia accumulate in order to remove the plaques by phagocytosis 
(Streit, 2004). However, the cluster of microglia produce a number of various neurotoxic 
substances thereby inducing inflammatory processes, possibly contributing to the 
neurodegeneration process (Akiyama et al., 2000; Streit, 2004). Astrocytes proliferate as a 
reaction to neuronal insults, and astrogliosis is thus also a phenomenon in the AD brain 
(Porchet et al., 2003). Moreover, astrocytes may impair the efficacy of microglia to remove 
the plaques (Akiyama et al., 2000).  
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Molecular imaging of the entities involved in neuroinflammation process that follows 
plaque formation is today possible, as a result of the development of a number of new 
different radiotracers labeling microglia or astrocytes (Akiyama et al., 2000). For the study of 
activated microglia, ligands labeling the peripheral benzodiazepine receptor (translocator 
protein 18 kDa) are used, such as PK11195 and analogues (Banati, 2002; Cagnin et al., 2002). 
Astrocytes, which also are involved in the neuroinflammatory process, may be studied 
using a tracer labeling the monoamine oxidase B (MAO-B) enzyme, such as deprenyl. 
However, deprenyl is rapidly metabolized in vivo, which can be diminished by using a di-
deuteriated deprenyl (Bergström et al., 1998; Fowler et al., 1988; Logan et al., 2000). 
3. Chemistry 
The highly conjugated fluorescent staining agents Congo red and chrysamine G (figure 2) 
were the first selected target molecules for the development of Aβ imaging ligands. 
However, those compounds were not suitable in vivo due to their low brain penetration 
ability (Klunk et al., 1994; Klunk et al., 1995). A number of other compounds with various 
chemical structures and promising Aβ binding abilities have been developed during last 
couple of years (Henriksen et al., 2008; Ono, 2009). Among those the most successful one so 
far is [11C]PIB or [11C]6-OH-BTA-1. All these compounds are small molecules with a central 
lipophilic group, a secondary or tertiary amine at one end and a polar or non-polar group at 
the other end. The terminal amine group and the middle lipophilic group which are the 
common features of all so far published molecules might have some impact on their 
amyloid binding properties. A list of available Aβ imaging PET ligands together with their 
chemical names and structures is presented in table 1. 
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Fig. 2. Chemical structures of Congo red, chrysamine G and thioflavin T. 
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Short names Chemical names Structures 
[11C]AZD2184 
N-[11C]methyl)-2-(6-
methylamino-pyridin-3-yl)-
benzo[d]thiazol-6-ol N
S
N
N
H
C
11OH
H3
 
[11C]BF-145 
2-(4-[N-Methyl-
11C]methylaminostyryl)-5-
fluorobenzoxazole O
N N
H
C
11
F
H3
 
[18F]BF-168 
2-(4-methylaminostyryl)-6-(2-
[18F]fluoroethoxy)benzoxazole 
O
N
O
F
18
N
H
CH
3
 
[18F]BF-227 
2-(2-[2-dimethylaminothiazol-5-
yl]ethenyl)-6-(2-
[18F]fluoroethoxy)benzoxazole O
N
O
F
18
S
N
N
CH
3
CH
3
 
[11C]BF-227 
[11C]2-(2-[2-
dimethylaminothiazol-5-
yl]ethenyl)-6-(2-
fluoroethoxy)benzoxazole 
O
N
O
F
S
N
N
CH
3
C
11
H3
 
[18F]FDDNP 
2-(1-(2-(N-(2-[18F]fluoroethyl)-
N-methylamino)naphthalene-6-
yl)ethylidene)malononitrile N
F
18
CH
3
CH
3
CNNC
 
[18F]FEM-
IMPY 
6-iodo-2-[4´-N-(2-
[18F]fluoroethyl)methylamino] 
phenyl-imidazo[1,2-a]pyridine 
N
N
I
N
F
18
 
[18F]FPM-
IMPY 
6-iodo-2-[4´-N-(2-
[18F]fluoropropyl)methylamino]
phenyl-imidazo[1,2-a]pyridine 
N
N
I
N
F
18
 
[18F]florbetabe
n ([18F]BAY94-
9172) 
4-(N-methylamino)-4´-(2-(2-(2-
[18F]fluoroethoxy)-ethoxy)-
ethoxy)-stilbene 
O
O
N
H
CH
3
O
F
18  
[18F]florbetapi
r ([18F]AV-45) 
N-{4-[2-(4-{2-[2-(2-
[18F]fluoroethoxy)ethoxy] 
ethoxy}-phenyl)vinyl]phenyl}-
N-methylamine 
N
O
O
N
H
CH
3
O
F
18  
[18F]flutemeta-
mol 
2-[3-[18F]fluoro-4-
(methylamino)phenyl]1,3-
benzothiazol-6-ol 
N
SOH
N
H
CH
3
F
18
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Short names Chemical names Structures 
[11C]MeS-
IMPY 
[S-methyl-11C]N,N-dimethyl-4-
(6-(methylthio)imidazo[1,2-
a]pyridine-2-yl)aniline 
N
N
N
S
C
11
H3
 
[11C]PIB [
11C]-2-4-(methylaminophenyl)-
6-hydroxybenzothiazole 
N
SOH
N
H
C
11
 
[11C]SB-13 [
11C]4-N-methylamino-4´-
hydroxystilbene 
OH
N
H
C
11
H
 
Table 1. Aβ imaging PET ligands 
3.1 Synthesis of 
11
C-and 
18
F-labeled Aβ binding PET ligands 
The Aβ binding PET ligands have been labeled with the ideal positron emitting 
radionuclides 11C or 18F, and the terminal amino or hydroxyl group of the molecule is 
mainly selected as the suitable 11C or 18F-labeling position. In case of [18F]flutemetamol, the 
labeling strategy was different and one of the aromatic ring of the lipophilic part of the 
molecule was selected for that purpose. 
3.1.1 Synthesis of 
11
C-labeled ligands  
The commonly used method for the synthesis of 11C-labeled Aβ binding PET ligands is the 
methylation using [11C]methyl iodide or [11C]methyl triflate. The cyclotron produced 
[11C]carbon dioxide is first converted to [11C]methyl iodide or [11C]methyl triflate which 
react with the desmethyl precursor of the corresponding target molecule to give the final 
11C-labeled product. A typical example of methylation using [11C]methyl iodide is the 
synthesis of [11C]PIB or [11C]6-OH-BTA-1. N-Methylation of methoxymethyl (MOM) 
protected BTA using [11C]methyl iodide in presence of potassium hydroxide followed by 
deprotection of MOM by treating with 50:50 mixture of methanol and concentrated 
hydrochloric acid gave the target compound [11C]PIB (Scheme 1) (Mathis et al., 2003). Other 
Aβ binding PET ligands prepared by methylation using [11C]methyl iodide are 
[11C]AZD2184 (Andersson et al., 2010), [11C]BF-145 (Shimadzu et al., 2004) and [11C]MeS-
IMPY (Seneca et al., 2007).  
The synthesis of the 11C-labeled stilbene derivative [11C]SB-13 is an example of methylation 
using [11C]methyl triflate. The synthesis was performed in a HPLC sample loop (Scheme 1) 
(Ono et al., 2003). Some other known Aβ binding PET ligands prepared by methylation 
using [11C]methyl triflate are [11C]BF-227 (Kudo et al., 2007), [11C]IMPY (Cai et al., 2008), 
benzofuran derivatives (Ono et al., 2006) and analogues of aminophenylbenzothiazoles with 
a fluorine substituted phenyl ring (Henriksen et al., 2007). 
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 Scheme 1. Synthesis of [11C]PIB and [11C]SB-13 
3.1.2 Synthesis of 
18
F-labeled ligands 
The commonly used 18F-labeling strategy for Aβ binding PET ligands is the aliphatic 
nucleophilic fluorination of the corresponding tosylate or mesylate precursors of the target 
molecules using non carrier added [18F]fluoride. A number of ligands have been prepared 
using this method and the followings are examples of such Aβ ligands. Two benzoxazole 
derivatives [18F]BF-168 (Shimadzu et al., 2004) and [18F]BF-227 (Okamura et al., 2007) were 
prepared by aliphatic nucleophilic fluorination of the corresponding 6-(2-tosyloxyethoxy)-
benzoxazole derivatives using [18F]fluoride ion in presence of potassium carbonate and 
kryptofix (Scheme 2). Other 18F-labeled Aβ ligands prepared by aliphatic nucleophilic 
fluorination are [18F]fluoropegylated stilbene derivatives [18F]florbetapir ([18F]AV-45) (Yao et 
al., 2010) and [18F]florbetaben ([18F]BAY 94-9172) (Wang et al., 2011; Zhang et al., 2005), 
amino naphthalene derivative [18F]FDDNP (Klok et al., 2008; Liu et al., 2007), and 
phenylimidazole derivatives [18F]FEM-IMPY and [18F]FPM-IMPY (Cai et al., 2004). Only one 
of all amyloid binding ligands published so far has been prepared by aromatic nucleophilic 
fluorination. This ligand is a 18F-labeled analogue of BTA known as [18F]flutemetamol (or 
[18F]FPIB, [18F]GE-067). The precursor contains a nitro group situated ortho to a 
carboxamide group on one of the aromatic ring which is substituted by no-carrier added 
[18F]fluoride to give the target compound (Scheme 3) (Koole et al., 2009; Storey et al., 2007). 
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Scheme 2. Synthesis of [18F]BF-168 and [18F]BF-227 
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Scheme 3. Synthesis of [18F]flutemetamol ([18F]FPIB) 
4. Evaluation of amyloid binding PET ligands 
An important part of the development of new potential tracers for visualizing amyloid with 
PET is the preclinical evaluation of these compounds. Several complementary in vitro and in 
vivo animal techniques are used for the evaluation which has to be performed before the 
new tracer can be given to humans. These techniques aim at finding compounds with 
optimal affinity for the target (Aβ), while having as low binding as possible to other targets. 
Moreover, the kinetics needs to be suitable for PET, i.e. the binding equilibrium should be 
reached in the time frame of a PET experiment. These and other important criteria for a 
suitable PET ligand need to be studied in the preclinical evaluation phase. 
Homogenate binding assay is a standard technique for the determination of affinity and 
selectivity of any compound. However, many of the parameters obtained in homogenate 
binding studies can also be obtained using in vitro cryosection autoradiography. After the 
process of evaluating the binding properties of a compound to be developed into a tracer to 
be used in PET or SPECT, homogenate binding studies may be used for determining of the 
absolute density of amyloid plaques in a tissue homogenate.  
Autoradiography is a commonly used method in the study of radioligands for use in PET or 
SPECT, as direct comparisons of in vitro autoradiography images can be made with in vivo 
PET images labeled with 11C and 18F. Autoradiography gives information on distribution, 
selectivity and nonspecific binding, as well as a number of kinetic parameters which all are 
parameters indicative of usefulness for in vivo molecular imaging. With regard to 
visualization of amyloid plaques in vivo, cryosection autoradiography is often used in 
comparison of different potential ligands, for example in structure activity relationship 
studies. Furthermore, the much higher resolution with in vitro autoradiography as 
compared with in vivo PET makes the former technique a complementary technique.  
It is obvious that certain parameters can be determined solely by an in vivo administration. 
For example, of great importance with regard to visualization of amyloid plaques in vivo is 
the extent of BBB penetration. In this case, “ex vivo” autoradiography could be preferred. 
Here “ex vivo” is defined as administration of the radioligand in vivo followed by 
autoradiography in vitro, and at least some of the above mentioned parameters can be 
determined. On the other hand, some parameters might be very difficult, if not impossible, 
to determine in vivo, such as to determine if an interaction really is saturable or not. Many of 
the compounds developed as tracers cannot be given in high enough concentrations to 
determine this, due to known toxicity or lack of toxicity information. For example, in spite of 
the numerous clinical studies performed with [11C]PIB, saturating amounts of [11C]PIB 
cannot be given to living subjects, and from in vivo PET it is not known if all [11C]PIB 
binding can be blocked by excess unlabeled PIB in vivo. Using in vitro autoradiography the 
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binding was blocked totally by adding 1000-fold higher concentration with unlabeled PIB 
(figure 3) (Långström et al., 2007; Svedberg et al., 2009). 
 
Fig. 3. Autoradiograms showing effects of PIB, flutemetamol (FPIB) and thioflavin on 
[18F]flutemetamol binding to sections of the temporal cortex of an AD patient. 
5. Results 
5.1 In vitro binding of PIB to postmortem AD brain 
Binding of [3H]PIB binding to insoluble Aβ deposits in postmortem brain obtained from AD 
patients has been reported by several investigators. In vitro studies have shown that the Kd 
for [3H]PIB binding to AD brain (3-4 nM) is similar to the Kd for binding synthetic Aβ1-40 
and Aβ1-42 fibrils (1 nM) (Fodero-Tavoletti et al., 2007; Ikonomovic et al., 2008; Kadir et al., 
2011; Klunk et al., 2005). In some AD and control brain homogenates as well as with Aβ 
synthetic fibrils a lower-affinity [3H]PIB binding site with Kd values of 75-250 nM have been 
observed (Ikonomovic et al., 2008; Klunk et al., 2005). However, these low-affinity sites 
would not contribute significantly to in vivo binding at [11C]PIB concentrations around 1 nM. 
No significant correlation of [3H]PIB binding with soluble Aβ peptides has been observed 
(Ikonomovic et al., 2008; Klunk et al., 2005). The requirement that Aβ be in fibrillar form for 
PIB binding was verified by showing that the highly fluorescent PIB derivative 6-CN-PIB 
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labeled both Aβ42 -and Aβ40-immunoreactive plaques whereas no labeling was detected in 
tissue sections pre-treated with formic acid which disrupts β-pleated sheets (Ikonomovic et 
al., 2008). 
Several studies have reported correlations between in vivo [11C]PIB retention and with 
region-matched postmortem quantification of [3H]PIB binding, Aβ plaque loads and Aβ 
peptide levels but not with neurofibrillar tangles (Bacskai et al., 2007; Ikonomovic et al., 
2008; Kadir et al., 2011; Rosen et al., 2011). In addition, a direct correlation between [11C]PIB 
binding and insoluble Aβ levels determined by ELISA in homogenates of AD brain has been 
observed (Ikonomovic et al., 2008; Kadir et al., 2011; Klunk et al., 2005; Rosen et al., 2011; 
Svedberg et al., 2009). 
Although several clinical PET studies with [11C]PIB have been performed (Engler et al., 2003; 
Engler et al., 2006; Klunk et al., 2003; Klunk et al., 2004), in vitro evaluation studies have 
provided us with important new information. In agreement with others (Fodero-Tavoletti et 
al., 2007; Klunk et al., 2005; Rosen et al., 2011) our recent in vitro study (Svedberg et al., 2009) 
revealed significantly higher binding of PIB in AD brain compared to control brain when 
using [11C]PIB autoradiography and [11C]PIB radioligand assay. Moreover, we observed no 
specific [11C]PIB binding in the cerebellum which is often used as a reference region for 
quantification of [11C]PIB retention in PET studies. For example, the distribution of [11C]PIB 
was investigated using autoradiography on tissue from patients that suffered from AD 
(Svedberg et al., 2009), which demonstrated that the binding is confined to external layers of 
the cerebral cortex, which due to a lower resolution is not seen in PET (figure 4). 
 
Fig. 4. [11C]PIB binding in the temporal cortex of an AD patient and microscopic images of 
the sections used. Autoradiograms depicting total (a and b) and nonspecific binding (d and 
e) of [11C]PIB in the temporal cortex of a patient with AD and microscopic images of the 
sections used (c and f). The yellow lines in B and E were drawn as regions of interest; the 
gray and the white matter area, respectively, on the microscopic images and were 
transferred to the autoradiograms. From Svedberg et al. (2009). 
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By using a combination of autoradiography and histochemical techniques Lockhart et al. 
(2007) showed that PIB, in addition to binding senile plaques (dense core plaques) also 
bound to cerebral amyloid angiopathy (CAA) and some diffuse plaques. In contrast to senile 
plaques where Aβ42 are much more abundant (Hellström-Lindahl et al., 2004; Näslund et 
al., 2000), the major amyloid peptide species in CAA is Aβ40 with less amounts of Aβ42 
(Mann et al., 1996). CAA is present in 80% or more of AD patients (Jellinger, 2002) and may 
therefore contribute significantly to the in vivo [11C]PIB signal and in vitro binding of PIB 
(Bacskai et al., 2007; Johnson et al., 2007; Svedberg et al., 2009). 
PIB binds only weakly to Aβ deposits in nonhuman species (Klunk et al., 2005; Rosen et al., 
2011). Recently, Rosen et al (2011) showed that despite levels of Aβ in cortical extracts that 
sometimes exceeded those in AD brain, high-affinity [3H]PIB in vitro binding in nonhuman 
primates (aged chimpanzees, rhesus macaques, and squirrel monkeys) was strikingly less 
than that in humans with AD. Similarly, less [3H]PIB binding was detected in homogenates 
of transgenic PS1/APP mouse brain compared to AD brain, despite higher Aβ levels (Klunk 
et al., 2005). A substantial difference in the intensity of [11C]PIB labeling between AD brain 
and APP transgenic mice has also been shown by ex vivo autoradiography (Maeda et al., 
2007).  
5.2 In vivo animal studies 
Two major in vivo modalities are of importance in the evaluation of new PET ligands. One is 
organ distribution studies in normal mice or rats, which gives information on to where the 
compound and its metabolites distribute. Organ distribution studies are also used in 
calculation of dosimetry, i.e. how much of a radiolabeled compound can be given without 
reaching radioactive doses that may risk damages due to radiation. 
A more obvious modality is the use of animal PET. In order to study binding to Aβ plaques 
transgenic animals are required, as plaques are not found naturally in old rats or mice 
(Philipson et al., 2010). Transgenic mouse models have become an important and valuable 
research tool in neurodegenerative disorders like AD. Attempts to model and study in detail 
longitudinal pathological processes in living brains and molecular mechanisms involved in 
the pathogenesis of the disease can provide insight into disease progression in AD patients. 
Transgenic mice of different types have been developed, all with amyloid plaques in the 
brain (Elder et al., 2010; Lannfelt et al., 1993; Morrissette et al., 2009). In the early animal PET 
studies using transgenic animals no binding of [11C]PIB was seen, in spite of a high amyloid 
load in the animal brains (Klunk et al., 2005; Toyama et al., 2005; Ye et al., 2006), The 
inconsistency between AD patients and transgenic mice models was for long unclear and 
explained by fewer binding sites or lower binding affinity of [11C]PIB for Aβ plaques in 
transgenic mice (Klunk et al., 2005; Toyama et al., 2005) and/or that the Aβ containing 
plaques in the mice resembles synthetic Aβ, where low [11C]PIB binding was demonstrated 
(Ye et al., 2006). It was demonstrated that intrinsic mouse Aβ is formed and deposited in 
significant amounts in the brain of an AD mouse model and is deposited together with 
human Aβ, and this might also explain the low efficacy of PIB binding in transgenic mice 
brain tissue (van Groen et al., 2006). Few years later it was demonstrated that the specific 
radioactivity of the tracer significantly contributed to the detection of the amyloid deposits 
in the mouse brain. High-level retention of [11C]PIB in APP transgenic mice brain regions 
known to contain amyloid was obtained when high-specific activity [11C]PIB was 
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administrated (Maeda et al., 2007). It might also depend on the type of transgenic animal 
used, as ex vivo studies using [3H]PIB and a new transgenic animal model, ARTE10, clearly 
showed intense labeling of the amyloid in these animals (Willuweit et al., 2009). 
Senile plaques are generally enriched in Aβ 1-42 species and are additionally subjected to a 
wide range of post-translational and post-deposition modifications, such as N-and C-
terminal truncation, oxidation, and isomerization (Lockhart, 2006). The N-terminally 
truncated and modified Aβ, AβN3-pyroglutamate, has been identified in AD brain (Wirths 
et al., 2010) and suggested to be a major contributor to PIB binding (Maeda et al., 2007). 
Compared to AD brain, this Aβ subtype is not so abundant in transgenic mice (Güntert et 
al., 2006; Kawarabayashi et al., 2001), and the levels of AβN3-pyroglutamate may therefore 
provide another plausible explanation for the difference in [11C]PIB binding between 
humans and mice. 
5.3 Clinical PET 
[11C]PIB, developed in collaboration between Uppsala University in Sweden and University 
of Pittsburgh School of Medicine, PA, USA, was the first tracer to detect Aβ in the brain of 
living patients (figure 5) (Klunk et al., 2004). The results demonstrated an increased [11C]PIB 
retention in several brain regions known to contain Aβ in AD and none in controls (Klunk et 
al., 2004). The [11C]PIB signal in the cortex was approximately 1.5-2 fold higher in the AD 
patients compared to the control subjects (Klunk et al., 2004). Interestingly enough, 
postmortem studies of the same patients that showed elevated [11C]PIB retention in vivo 
during their life correlates significantly with regional in vitro measures of Aβ pathology 
found at autopsy (Ikonomovic et al., 2008; Kadir et al., 2011). 
 
 
Fig. 5. [11C]PIB amyloid binding to the brains of two AD patients and one healthy control 
(sagittal sections). Red indicates high, yellow medium, blue low [11C]PIB retention. MMSE 
Mini-Mental- State-Examination, vs. years. Figure adapted from Nordberg (2008). 
Since the study reported by Klunk et al. (2004) several selective amyloid ligands are under 
study or have been studied in vivo in living patients (see table 1). Regardless of compelling 
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results with [11C]PIB the short half-life limits the use of PIB and other 11C-ligands. This 
emphasizes the need for 18F-ligands, with longer half-life, to implement a broader Aβ PET 
imaging. Recently, [18F]AV-45 PET imaging was performed in AD patients and control 
subjects (Wong et al., 2010). The results revealed an increase in [18F]AV-45 retention in the 
cortical gray matter in the AD patients, areas that expected to have high Aβ accumulation 
and none in the control subjects (Wong et al., 2010) similar to previously reported for 
[11C]PIB.  
6. Conclusion  
The development of plaques are very early events in the course of events leading to AD 
(Ingelsson et al., 2004; Långström et al., 2007), and imaging plaques in early stages of the 
disease would be of great value for the treatment. However, the “ceiling effect”, i.e. that the 
amount of amyloid plaques reaches maximum already early in the disease (Engler et al., 
2006; Nordberg, 2007), makes it difficult to follow the slow progression of the disease using 
in vivo imaging of amyloid plaques. The large number of compounds that are under 
development or are today used in in vivo PET or SPECT investigations of amyloid plaques 
all aim at visualizing the same entities, and will hardly overcome this problem. New ligands 
that visualize the formation of plaques earlier in the course of disease are therefore needed. 
The presently available compounds bind to plaques, but some are also binding to earlier 
stages in the formation of plaques, such as to fibrils and oligomers, and might therefore be 
of great value for finding new treatment of AD and thus also for the individual patients.  
There is also great interest in finding a specific radioligand for the visualization of 
neurofibrillary tangles, which is another hallmark seen in AD. Some of the ligands binding 
to the amyloid plaques also bind to some extent to tangles, and further development of 
these compounds may lead to ligands also labeling tangles (see e.g Barrio et al., 2008; 
Okamura et al., 2005; Shoghi-Jadid et al., 2002; Åslund et al., 2009). The development of 
tracers labeling tangles should be complementing the tracers labeling amyloid discussed 
above.  
It can be concluded that the use of PET in the evaluation of AD has alleviated the diagnosis 
of the disease considerably. The development of new tracers with even better properties and 
tracers labeling amyloid fibrils and neurofibrillary tangles is therefore still a highly 
prioritized research area. 
7. Acknowledgment  
We are grateful for valuable discussions with Prof. Bengt Långström and our colleagues at 
Uppsala University. This study was performed when authors OR and HH were employed at 
Uppsala Applied Science Lab, GE Healthcare. We are grateful to a SAMBIO funding from 
Vinnova, Sweden. 
8. References 
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., 
Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, 
W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., 
www.intechopen.com
 
Positron Emission Tomography – Current Clinical and Research Aspects 
 
268 
McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., 
Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., 
Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G. & Wyss-Coray, T. 
(2000) Inflammation and Alzheimer's disease. Neurobiology of Aging, Vol. 21, No. 3, 
pp. 383-421, 0197-4580 (Print), 0197-4580 (Linking). 
Alzheimer, A. (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allegemeine Zeitschrift 
für Psychiatrie und Psychisch-Gerchtliche Medizin, Vol. 64, No. pp. 146-148. 
Andersson, J.D., Varnäs, K., Cselenyi, Z., Gulyas, B., Wensbo, D., Finnema, S.J., Swahn, B.-
M., Svensson, S., Nyberg, S., Farde, L. & Halldin, C. (2010) Radiosynthesis of the 
candidate beta-amyloid radioligand [11C]AZD2184: Positron emission tomography 
examination and metabolite analysis in cynomolgus monkeys. Synapse, Vol. 64, No. 
10, pp. 733-741.  
Archer, H.A., Edison, P., Brooks, D.J., Barnes, J., Frost, C., Yeatman, T., Fox, N.C. & Rossor, 
M.N. (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB 
positron emission tomography study. Annals of Neurology, Vol. 60, No. 1, pp. 145-
147, 0364-5134 (Print), 0364-5134 (Linking). 
Bacskai, B.J., Frosch, M.P., Freeman, S.H., Raymond, S.B., Augustinack, J.C., Johnson, K.A., 
Irizarry, M.C., Klunk, W.E., Mathis, C.A., Dekosky, S.T., Greenberg, S.M., Hyman, 
B.T. & Growdon, J.H. (2007) Molecular imaging with Pittsburgh Compound B 
confirmed at autopsy: a case report. Archives of Neurology, Vol. 64, No. 3, pp. 431-
434.  
Banati, R.B. (2002) Visualising microglial activation in vivo. Glia, Vol. 40, No. 2, pp. 206-217, 
0894-1491 (Print), 0894-1491 (Linking). 
Barrio, J.R., Kepe, V., Satyamurthy, N., Huang, S.C. & Small, G. (2008) Amyloid and tau 
imaging, neuronal losses and function in mild cognitive impairment. The Journal of 
Nutrition, Health & Aging, Vol. 12, No. 1, pp. 61S-65S, 1279-7707 (Print), 1279-7707 
(Linking). 
Bergström, M., Kumlien, E., Lilja, A., Tyrefors, N., Westerberg, G. & Långström, B. (1998) 
Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--
analysis of kinetic data. Acta Neurologica Scandinavica, Vol. 98, No. 4, pp. 224-231, 
0001-6314 (Print), 0001-6314 (Linking). 
Braak, H., de Vos, R.A., Jansen, E.N., Bratzke, H. & Braak, E. (1998) Neuropathological 
hallmarks of Alzheimer's and Parkinson's diseases. Progress in Brain Research, Vol. 
117, No. pp. 267-285.  
Cagnin, A., Gerhard, A. & Banati, R.B. (2002) In vivo imaging of neuroinflammation. 
European Neuropsychopharmacology, Vol. 12, No. 6, pp. 581-586, 0924-977X (Print), 
0924-977X (Linking). 
Cai, L., Chin, F.T., Pike, V.W., Toyama, H., Liow, J.S., Zoghbi, S.S., Modell, K., Briard, E., 
Shetty, H.U., Sinclair, K., Donohue, S., Tipre, D., Kung, M.P., Dagostin, C., 
Widdowson, D.A., Green, M., Gao, W., Herman, M.M., Ichise, M. & Innis, R.B. 
(2004) Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethyl-
amino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for -
amyloid in Alzheimer's disease. Journal of Medicinal Chemistry, Vol. 47, No. 9, pp. 
2208-2218.  
Cai, L., Liow, J.-S., Zoghbi, S.S., Cuevas, J., Baetas, C., Hong, J., Shetty, H.U., Seneca, N.M., 
Brown, A.K., Gladding, R., Temme, S.S., Herman, M.M., Innis, R.B. & Pike, V.W. 
(2008) Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-
www.intechopen.com
 
Amyloid Imaging PET Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation 
 
269 
methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as 
radioligands for Imaging -amyloid plaques in Alzheimer's disease. Journal of 
Medicinal Chemistry, Vol. 51, No. 1, pp. 148-158.  
Elder, G.A., Gama Sosa, M.A. & De Gasperi, R. (2010) Transgenic mouse models of 
Alzheimer's disease. Mount Sinai Journal of Medicine, Vol. 77, No. 1, pp. 69-81, 1931-
7581 (Electronic), 0027-2507 (Linking). 
Engler, H., Lundberg, P.O., Ekbom, K., Nennesmo, I., Nilsson, A., Bergström, M., Tsukada, 
H., Hartvig, P. & Långström, B. (2003) Multitracer study with positron emission 
tomography in Creutzfeldt-Jakob disease. European Journal of Nuclear Medicine and 
Molecular Imaging, Vol. 30, No. 1, pp. 85-95, 1619-7070 (Print), 1619-7070 (Linking). 
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., 
Ringheim, A., Långström, B. & Nordberg, A. (2006) Two-year follow-up of amyloid 
deposition in patients with Alzheimer's disease. Brain, Vol. 129, No. Pt 11, pp. 2856-
2866.  
Ewers, M., Walsh, C., Trojanowski, J.Q., Shaw, L.M., Petersen, R.C., Jack, C.R., Jr., Feldman, 
H.H., Bokde, A.L., Alexander, G.E., Scheltens, P., Vellas, B., Dubois, B., Weiner, M. 
& Hampel, H. (2010) Prediction of conversion from mild cognitive impairment to 
Alzheimer's disease dementia based upon biomarkers and neuropsychological test 
performance. Neurobiology of Aging, Vol. No. pp. 1558-1497 (Electronic), 0197-4580 
(Linking). 
Fodero-Tavoletti, M.T., Smith, D.P., McLean, C.A., Adlard, P.A., Barnham, K.J., Foster, L.E., 
Leone, L., Perez, K., Cortes, M., Culvenor, J.G., Li, Q.X., Laughton, K.M., Rowe, 
C.C., Masters, C.L., Cappai, R. & Villemagne, V.L. (2007) In vitro characterization of 
Pittsburgh compound-B binding to Lewy bodies. Journal of Neurochemistry, Vol. 27, 
No. 39, pp. 10365-10371, 1529-2401 (Electronic), 0270-6474 (Linking). 
Fowler, J.S., Wolf, A.P., MacGregor, R.R., Dewey, S.L., Logan, J., Schlyer, D.J. & Långström, 
B. (1988) Mechanistic positron emission tomography studies: demonstration of a 
deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-
deprenyl in living baboon brain. Journal of Neurochemistry, Vol. 51, No. 5, pp. 1524-
1534, 0022-3042 (Print), 0022-3042 (Linking). 
Ganguli, M. & Petersen, R.C. (2008) Mild cognitive impairment: challenging issues. American 
Journal of Geriatric Psychiatry, Vol. 16, No. 5, pp. 339-342, 1545-7214 (Electronic), 
1064-7481 (Linking). 
Ganguli, M., Blacker, D., Blazer, D.G., Grant, I., Jeste, D.V., Paulsen, J.S., Petersen, R.C. & 
Sachdev, P.S. (2011) Classification of neurocognitive disorders in DSM-5: a work in 
progress. American Journal of Geriatric Psychiatry, Vol. 19, No. 3, pp. 205-210, 1545-
7214 (Electronic), 1064-7481 (Linking). 
Güntert, A., Döbeli, H. & Bohrmann, B. (2006) High sensitivity analysis of amyloid-beta 
peptide composition in amyloid deposits from human and PS2APP mouse brain. 
Neuroscience, Vol. 143, No. 2, pp. 461-475, 0306-4522 (Print), 0306-4522 (Linking). 
Hellström-Lindahl, E., Mousavi, M., Ravid, R. & Nordberg, A. (2004) Reduced levels of 
Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. 
Neurobiology of Disease, Vol. 15, No. 2, pp. 351-360.  
Henriksen, G., Hauser, A.I., Westwell, A.D., Yousefi, B.H., Schwaiger, M., Drzezga, A. & 
Wester, H.-J. (2007) Metabolically stabilized benzothiazoles for imaging of amyloid 
plaques. Journal of Medicinal Chemistry, Vol. 50, No. 6, pp. 1087-1089.  
www.intechopen.com
 
Positron Emission Tomography – Current Clinical and Research Aspects 
 
270 
Henriksen, G., Yousefi, B.H., Drzezga, A. & Wester, H.-J. (2008) Development and 
evaluation of compounds for imaging of beta-amyloid plaque by means of positron 
emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 
Vol. 35, No. Suppl 1, pp. S75-S81.  
Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., 
Lopresti, B.J., Ziolko, S., Bi, W., Paljug, W.R., Debnath, M.L., Hope, C.E., Isanski, 
B.A., Hamilton, R.L. & DeKosky, S.T. (2008) Post-mortem correlates of in vivo PiB-
PET amyloid imaging in a typical case of Alzheimer's disease. Brain, Vol. 131, No. Pt 
6, pp. 1630-1645, 1460-2156 (Electronic). 
Ingelsson, M., Fukumoto, H., Newell, K.L., Growdon, J.H., Hedley-Whyte, E.T., Frosch, 
M.P., Albert, M.S., Hyman, B.T. & Irizarry, M.C. (2004) Early Abeta accumulation 
and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 
Vol. 62, No. 6, pp. 925-931.  
Jellinger, K.A. (2002) Alzheimer disease and cerebrovascular pathology: an update. Journal of 
Neural Transmission, Vol. 109, No. 5-6, pp. 813-836, 0300-9564 (Print), 0300-9564 
(Linking). 
Johnson, K.A., Gregas, M., Becker, J.A., Kinnecom, C., Salat, D.H., Moran, E.K., Smith, E.E., 
Rosand, J., Rentz, D.M., Klunk, W.E., Mathis, C.A., Price, J.C., Dekosky, S.T., 
Fischman, A.J. & Greenberg, S.M. (2007) Imaging of amyloid burden and 
distribution in cerebral amyloid angiopathy. Annals of Neurology, Vol. 62, No. 3, pp. 
229-234, 0364-5134 (Print), 0364-5134 (Linking). 
Kadir, A., Marutle, A., Gonzalez, D., Scholl, M., Almkvist, O., Mousavi, M., Mustafiz, T., 
Darreh-Shori, T., Nennesmo, I. & Nordberg, A. (2011) Positron emission 
tomography imaging and clinical progression in relation to molecular pathology in 
the first Pittsburgh Compound B positron emission tomography patient with 
Alzheimer's disease. Brain, Vol. 134, No. Pt 1, pp. 301-317, 1460-2156 (Electronic), 
0006-8950 (Linking). 
Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H. & Younkin, S.G. (2001) 
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the 
Tg2576 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience, Vol. 
21, No. 2, pp. 372-381.  
Klok, R.P., Klein, P.J., van Berckel, B.N.M., Tolboom, N., Lammertsma, A.A. & Windhorst, 
A.D. (2008) Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-
methylamino-naphthalene ([18F]FDDNP). Applied Radiation and Isotopes, Vol. 66, No. 
pp. 203-207.  
Klunk, W.E., Debnath, M.L. & Pettegrew, J.W. (1994) Development of small molecule probes 
for the beta-amyloid protein of Alzheimer's disease. Neurobiology of Aging, Vol. 15, 
No. pp. 691-698.  
Klunk, W.E., Debnath, M.L. & Pettegrew, J.W. (1995) Chrysamine-G binding to Alzheimer 
and control brain: Autopsy study of new amyloid probe. Neurobiology of Aging, Vol. 
16, No. 4, pp. 541-548.  
Klunk, W.E., Engler, H., Nordberg, A., Bacskai, B.J., Wang, Y., Price, J.C., Bergström, M., 
Hyman, B.T., Långström, B. & Mathis, C.A. (2003) Imaging the pathology of 
Alzheimer's disease: amyloid-imaging with positron emission tomography. 
Neuroimaging Clinics of North America, Vol. 13, No. 4, pp. 781-789, ix.  
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., 
Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, 
www.intechopen.com
 
Amyloid Imaging PET Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation 
 
271 
J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A. & 
Långström, B. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh 
Compound-B. Annals of Neurology, Vol. 55, No. 3, pp. 306-319.  
Klunk, W.E., Lopresti, B.J., Ikonomovic, M.D., Lefterov, I.M., Koldamova, R.P., Abrahamson, 
E.E., Debnath, M.L., Holt, D.P., Huang, G.F., Shao, L., DeKosky, S.T., Price, J.C. & 
Mathis, C.A. (2005) Binding of the positron emission tomography tracer Pittsburgh 
compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but 
not in transgenic mouse brain. Journal of Neuroscience, Vol. 25, No. 46, pp. 10598-
10606.  
Koole, M., Lewis, D.M., Buckley, C., Nelissen, N., Vandenbulcke, M., Brooks, D.J., 
Vandenberghe, R. & Van Laere, K. (2009) Whole-body biodistribution and radiation 
dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. Journal of 
Nuclear Medicine, Vol. 50, No. 5, pp. 818-822, 0161-5505 (Print). 
Korczyn, A.D. (2008) The amyloid cascade hypothesis. Alzheimers & Dementia, Vol. 4, No. 3, 
pp. 176-178, 1552-5279 (Electronic), 1552-5260 (Linking). 
Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., Itoh, M., 
Iwata, R., Yanai, K. & Arai, H. (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- 
(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense 
amyloid plaques in Alzheimer's disease patients. Journal of Nuclear Medicine, Vol. 
48, No. 4, pp. 553-561, 0161-5505 (Print), 0161-5505 (Linking). 
Lannfelt, L., Folkesson, R., Mohammed, A.H., Winblad, B., Hellgren, D., Duff, K. & Hardy, J. 
(1993) Alzheimer's disease: molecular genetics and transgenic animal models. 
Behavioural Brain Research, Vol. 57, No. 2, pp. 207-213, 0166-4328 (Print), 0166-4328 
(Linking). 
Liu, J., Kepe, V., Zabjek, A., Petric, A., Padgett, H.C., Satyamurthy, N. & Barrio, J.R. (2007) 
High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl) 
amino]-2-naphthyl}ethylidene)malononi trile ([18F]FDDNP) ready for animal or 
human administration. Molecular Imaging and Biology, Vol. 9, No. pp. 6-16.  
Lockhart, A. (2006) Imaging Alzheimer's disease pathology: one target, many ligands. Drug 
Discovery Today, Vol. 11, No. 23-24, pp. 1093-1099.  
Logan, J., Fowler, J.S., Volkow, N.D., Wang, G.J., MacGregor, R.R. & Shea, C. (2000) 
Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl 
([11C]L-deprenyl-D2) binding in the human brain. Nuclear Medicine and Biology, Vol. 
27, No. 1, pp. 43-49, 0969-8051 (Print), 0969-8051 (Linking). 
Långström, B., Andrén, P.E., Lindhe, Ö., Svedberg, M.M. & Hall, H. (2007) In vitro imaging 
techniques in neurodegenerative diseases. Molecular Imaging and Biology, Vol. 9, No. 
4, pp. 161-175, 1536-1632 (Print), 1536-1632 (Linking). 
Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, 
N., Ono, M., Saido, T.C., Suzuki, K., Mori, H., Higuchi, M. & Suhara, T. (2007) 
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-
amyloid treatment in a living mouse model of Alzheimer's disease enabled by 
positron emission tomography. Journal of Neuroscience, Vol. 27, No. 41, pp. 10957-
10968, 1529-2401 (Electronic), 0270-6474 (Linking). 
Mann, D.M., Iwatsubo, T., Ihara, Y., Cairns, N.J., Lantos, P.L., Bogdanovic, N., Lannfelt, L., 
Winblad, B., Maat-Schieman, M.L. & Rossor, M.N. (1996) Predominant deposition 
of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary 
www.intechopen.com
 
Positron Emission Tomography – Current Clinical and Research Aspects 
 
272 
cerebral hemorrhage associated with mutations in the amyloid precursor protein 
gene. American Journal of Pathology, Vol. 148, No. 4, pp. 1257-1266.  
Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L. & Klunk, W.E. (2003) 
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as 
amyloid imaging agents. Journal of Medicinal Chemistry, Vol. 46, No. 13, pp. 2740-
2754.  
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. & Stadlan, E.M. (1984) 
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work 
Group under the auspices of Department of Health and Human Services Task 
Force on Alzheimer's Disease. Neurology, Vol. 34, No. 7, pp. 939-944.  
Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk, W.E., 
Mathis, C.A., DeKosky, S.T. & Morris, J.C. (2006) [11C]PIB in a nondemented 
population: potential antecedent marker of Alzheimer disease. Neurology, Vol. 67, 
No. 3, pp. 446-452.  
Morrissette, D.A., Parachikova, A., Green, K.N. & LaFerla, F.M. (2009) Relevance of 
transgenic mouse models to human Alzheimer disease. Journal of Biological 
Chemistry, Vol. 284, No. 10, pp. 6033-6037, 0021-9258 (Print), 0021-9258 (Linking). 
Nordberg, A. (2004) PET imaging of amyloid in Alzheimer's disease. Lancet Neurology, Vol. 
3, No. 9, pp. 519-527. 
Nordberg, A. (2007) Amyloid imaging in Alzheimer's disease. Current Opinion in Neurology, 
Vol. 20, No. 4, pp. 398-402. 
Nordberg, A. (2008) Amyloid plaque imaging in vivo: current achievement and future 
prospects. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35 Suppl 
1, No. pp. S46-50, 1619-7070 (Print), 1619-7070 (Linking). 
Näslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P. & Buxbaum, 
J.D. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain 
and cognitive decline. JAMA, The Journal of American Medical Association, Vol. 283, 
No. 12, pp. 1571-1577.  
Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, 
T., Fujiwara, H., Nemoto, M., Maruyama, M., Arai, H., Yanai, K., Sawada, T. & 
Kudo, Y. (2005) Quinoline and benzimidazole derivatives: candidate probes for in 
vivo imaging of tau pathology in Alzheimer's disease. The Journal of Neuroscience, 
Vol. 25, No. 47, pp. 10857-10862, 1529-2401 (Electronic). 
Okamura, N., Furmoto, S., Funaki, Y., Suemoto, T., Kato, M., Ishikawa, Y., Ito, S., Akatsu, H., 
Yamamoto, T., Swada, T., Arai, H., Kudo, Y. & Yanai, K. (2007) binding and safety 
profile of novel derivative for in vivo imaging of amyloid deposite in Alzheimer's 
disease. Geriatrics & Gerontology International, Vol. 7, No. pp. 393-400.  
Ono, M., Wilson, A., Nobrega, J., Westaway, D., Verhoeff, P., Zhuang, Z.-P., Kung, M.-P. & 
Kung, H.F. (2003) 11C-Labeled stilbene derivatives as A-beta aggregate specific PET 
imaging agents for Alzheimer's disease. Nuclear Medicine and Biology, Vol. 30, No. 
pp. 565-571. 
Ono, M., Kawashima, H., Nonaka, A., Kawai, T., Haratake, M., Mori, H., Kung, M.-P., Kung, 
H.F., Saji, H. & Nakayama, M. (2006) Novel benzofuran derivatives for PET 
imaging of .beta.-amyloid plaques in Alzheimer's disease brains. Journal of 
Medicinal Chemistry, Vol. 49, No. 9, pp. 2725-2730. 
Ono, M. (2009) Development of positron-emission tomography/single-photon emission 
computed tomography imaging probes for in vivo detection of β-amyloid plaques 
www.intechopen.com
 
Amyloid Imaging PET Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation 
 
273 
in Alzheimer’s brains. Chemical & Pharmaceutical Bulletin, Vol. 57, No. 10, pp. 1029-
1039. 
Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Ritchie, K., Rossor, 
M., Thal, L. & Winblad, B. (2001) Current concepts in mild cognitive impairment. 
Archives of Neurology, Vol. 58, No. 12, pp. 1985-1992.  
Philipson, O., Lord, A., Gumucio, A., O'Callaghan, P., Lannfelt, L. & Nilsson, L.N. (2010) 
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS 
Journal, Vol. 277, No. 6, pp. 1389-1409, 1742-4658 (Electronic), 1742-464X (Linking). 
Porchet, R., Probst, A., Bouras, C., Draberova, E., Draber, P. & Riederer, B.M. (2003) Analysis 
of glial acidic fibrillary protein in the human entorhinal cortex during aging and in 
Alzheimer's disease. Proteomics, Vol. 3, No. 8, pp. 1476-1485, 1615-9853 (Print), 1615-
9853 (Linking). 
Rosen, R.F., Walker, L.C. & Levine, H., 3rd. (2011) PIB binding in aged primate brain: 
enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiology 
of Aging, Vol. 32, No. 2, pp. 223-234, 1558-1497 (Electronic), 0197-4580 (Linking). 
Schönheit, B., Zarski, R. & Ohm, T.G. (2004) Spatial and temporal relationships between 
plaques and tangles in Alzheimer-pathology. Neurobiology of Aging, Vol. 25, No. 6, 
pp. 697-711.  
Selkoe, D.J. & Schenk, D. (2003) Alzheimer's disease: molecular understanding predicts 
amyloid-based therapeutics. Annual Review of Pharmacology and Toxicology, Vol. 43, 
No. pp. 545-584, 0362-1642 (Print), 0362-1642 (Linking). 
Seneca, N., Cai, L., Liow, J.-S., Zoghbi, S.S., Gladding, R.L., Hong, J., Pike, V.W. & Innis, R.B. 
(2007) Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, 
a candidate radioligand for .beta.-amyloid plaques. Nuclear Medicine and Biology, 
Vol. 34, No. 6, pp. 681-689.  
Shimadzu, H., Suemoto, T., Suzuki, M., Shiomitsu, T., Okamura, N., Kudo, Y. & Sawada, T. 
(2004) Novel probes for imaging amyloid-b: F-18 and C-11 labeling of 2-(4-
aminostyryl)benzoxazole derivatives. Journal of Labelled Compounds and 
Radiopharmaceuticals., Vol. 47, No. pp. 181-190.  
Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., Kepe, V., Ercoli, L.M., Siddarth, P., Read, S., 
Satyamurthy, N., Petric, A., Huang, S.C. & Barrio, J.R. (2002) Localization of 
neurofibrillary tangles and -amyloid plaques in the brains of living patients with 
Alzheimer disease. The American Journal of Geriatric Psychiatry, Vol. 10, No. 1, pp. 24-
35, 1064-7481 (Print). 
Storey, A.E., Jones, C.L., Bouvet, D.R.C., Lasbistes, N., Fairway, S.M., Williams, L., Gibson, 
A.M., Nairne, R.J., Karimi, F. & Långström, B. (2007) Process for fluorination of 
anilides. PCT international applications WO 2006-GB3009 20060811, Vol. No. pp. 45.  
Streit, W.J. (2004) Microglia and Alzheimer's disease pathogenesis. Journal of Neuroscience 
Research, Vol. 77, No. 1, pp. 1-8, 0360-4012 (Print), 0360-4012 (Linking). 
Svedberg, M.M., Hall, H., Hellström-Lindahl, E., Estrada, S., Guan, Z., Nordberg, A. & 
Långström, B. (2009) [11C]PIB-amyloid binding and levels of Abeta40 and Abeta42 
in postmortem brain tissue from Alzheimer patients. Neurochemistry International, 
Vol. 54, No. 5-6, pp. 347-357, 1872-9754 (Electronic). 
Toyama, H., Ye, D., Ichise, M., Liow, J.S., Cai, L., Jacobowitz, D., Musachio, J.L., Hong, J., 
Crescenzo, M., Tipre, D., Lu, J.Q., Zoghbi, S., Vines, D.C., Seidel, J., Katada, K., 
Green, M.V., Pike, V.W., Cohen, R.M. & Innis, R.B. (2005) PET imaging of brain 
with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of 
www.intechopen.com
 
Positron Emission Tomography – Current Clinical and Research Aspects 
 
274 
Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 
32, No. 5, pp. 593-600, 1619-7070 (Print), 1619-7070 (Linking). 
van Groen, T., Kiliaan, A.J. & Kadish, I. (2006) Deposition of mouse amyloid  in human 
APP/PS1 double and single AD model transgenic mice. Neurobiology of Disease, Vol. 
23, No. 3, pp. 653-662.  
Wang, H., Shi, H., Yu, H., Jiang, S. & Tang, G. (2011) Facile and rapid one-step 
radiosynthesis of [18F]BAY94-9172 with a new precursor. Nuclear Medicine and 
Biology, Vol. 38, No. pp. 121-127.  
Villemagne, V.L., Pike, K.E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, 
T.F., Currie, J., Chan, S.G., Jones, G., Tochon-Danguy, H., O'Keefe, G., Masters, C.L. & 
Rowe, C.C. (2008) Abeta deposits in older non-demented individuals with cognitive 
decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, Vol. 46, No. 
6, pp. 1688-1697, 0028-3932 (Print), 0028-3932 (Linking). 
Willuweit, A., Velden, J., Godemann, R., Manook, A., Jetzek, F., Tintrup, H., Kauselmann, 
G., Zevnik, B., Henriksen, G., Drzezga, A., Pohlner, J., Schoor, M., Kemp, J.A. & von 
der Kammer, H. (2009) Early-onset and robust amyloid pathology in a new 
homozygous mouse model of Alzheimer's disease. PLoS One, Vol. 4, No. 11, pp. 
e7931, 1932-6203 (Electronic), 1932-6203 (Linking). 
Wimo, A. & Winblad, B. (2008) Economical aspects of dementia. Handbook of Clinical 
Neurology, Vol. 89, No. pp. 137-146, 0072-9752 (Print), 0072-9752 (Linking). 
Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P.J., Multhaup, G., 
Brody, D.L., Esparza, T., Ingelsson, M., Kalimo, H., Lannfelt, L. & Bayer, T.A. (2010) 
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial 
Alzheimer's disease cases. Journal of Neural Transmission, Vol. 117, No. 1, pp. 85-96, 
1435-1463 (Electronic), 0300-9564 (Linking). 
Wong, D.F., Rosenberg, P.B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H.T., Dannals, R.F., 
Nandi, A., Brasic, J.R., Ye, W., Hilton, J., Lyketsos, C., Kung, H.F., Joshi, A.D., 
Skovronsky, D.M. & Pontecorvo, M.J. (2010) In vivo imaging of amyloid deposition 
in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). 
Journal of Nuclear Medicine, Vol. 51, No. 6, pp. 913-920, 1535-5667 (Electronic), 0161-
5505 (Linking). 
Yao, C.-H., Lin, K.-J., Weng, C.-C., Hsiao, I.-T., Ting, Y.-S., Yen, T.-C., Jan, T.-R., Skovronsky, 
D., Kung, M.-P. & Wey, S.-P. (2010) GMP-compliant automated synthesis of 
[18F]AV-45 (Florbetapir F-18) for imaging beta-amyloid plaques in human brain. 
Applied Radiation and Isotopes, Vol. 68, No. pp. 2293-2297.  
Ye, L., Morgenstern, J.L., Lamb, J.R. & Lockhart, A. (2006) Characterisation of the binding of 
amyloid imaging tracers to rodent A fibrils and rodent-human A co-polymers. 
Biochemical and Biophysical Research Communications, Vol. 347, No. 3, pp. 669-677.  
Zhang, W., Oya, S., Kung, M.P., Hou, C., Maier, D.L. & Kung, H.F. (2005) F-18 stilbenes as PET 
imaging agents for detecting beta-amyloid plaques in the brain. Journal of Medicinal 
Chemistry, Vol. 48, No. 19, pp. 5980-5988, 0022-2623 (Print), 0022-2623 (Linking). 
Åslund, A., Sigurdson, C.J., Klingstedt, T., Grathwohl, S., Bolmont, T., Dickstein, D.L., 
Glimsdal, E., Prokop, S., Lindgren, M., Konradsson, P., Holtzman, D.M., Hof, P.R., 
Heppner, F.L., Gandy, S., Jucker, M., Aguzzi, A., Hammarström, P. & Nilsson, K.P. 
(2009) Novel pentameric thiophene derivatives for in vitro and in vivo optical 
imaging of a plethora of protein aggregates in cerebral amyloidoses. Acs Chemical 
Biology, Vol. 4, No. 8, pp. 673-684, 1554-8937 (Electronic), 1554-8929 (Linking). 
www.intechopen.com
Positron Emission Tomography - Current Clinical and Research
Aspects
Edited by Dr. Chia-Hung Hsieh
ISBN 978-953-307-824-3
Hard cover, 336 pages
Publisher InTech
Published online 08, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book's stated purpose is to provide a discussion of the technical basis and clinical applications of positron
emission tomography (PET), as well as their recent progress in nuclear medicine. It also summarizes current
literature about research and clinical science in PET. The book is divided into two broad sections: basic
science and clinical science. The basic science section examines PET imaging processing, kinetic modeling,
free software, and radiopharmaceuticals. The clinical science section demonstrates various clinical
applications and diagnoses. The text is intended not only for scientists, but also for all clinicians seeking recent
information regarding PET.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Marie Svedberg, Ewa Hellström-Lindahl, Obaidur Rahman and Håkan Hall (2012). Amyloid Imaging PET
Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation, Positron Emission Tomography -
Current Clinical and Research Aspects, Dr. Chia-Hung Hsieh (Ed.), ISBN: 978-953-307-824-3, InTech,
Available from: http://www.intechopen.com/books/positron-emission-tomography-current-clinical-and-research-
aspects/amyloid-imaging-pet-ligands-as-biomarkers-for-alzheimer-s-disease-preclinical-evaluation
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
